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Abstract: Premature ejaculation (PE) is a major issue in male sexual health. The global 
prevalence of PE is estimated to be between 20% and 40%, making it the most common 
sexual dysfunction in men. PE causes distress and reduced quality of life for patients and has a 
negative impact on interpersonal relationships. Historically, it has been treated with cognitive 
therapy, behavioral methods, and off-label use of selective serotonin reuptake inhibitors usually 
used to treat depression and other psychological disorders. Dapoxetine is a selective serotonin 
reuptake inhibitor specifically designed to treat PE. This paper reviews the current evidence 
for use of dapoxetine in the treatment of PE in adult men. There is substantial evidence that 
dapoxetine 30 mg or 60 mg taken “on-demand” results in a significant increase in intravaginal 
ejaculatory latency time when compared with placebo. Patient-reported outcomes are clearly 
improved relative to placebo following dapoxetine therapy, indicating greater control over 
ejaculation, more satisfaction with intercourse, less ejaculation-related distress, and, importantly, 
significantly reduced interpersonal difficulty. These data were supported by consistent reports of 
improvement in Clinical Global Impression of change in PE following treatment with dapoxetine. 
Further studies are needed to evaluate long-term efficacy and health economics. The unique 
pharmacology of dapoxetine makes it ideal for on-demand dosing, and the clinical evidence 
shows dapoxetine to be an efficacious and tolerable treatment for lifelong and acquired PE.
Keywords: dapoxetine, intravaginal ejaculatory latency time, patient-reported outcomes, 
premature ejaculation
Scope, aims, and objectives
Dapoxetine (PriligyTM, Johnson and Johnson, Raritan, NJ) is the first and only product 
licensed for the treatment of premature ejaculation (PE) in men aged 18–64 years. 
At present, dapoxetine is licensed in ten countries, including several countries in 
Europe, and Mexico, South Korea, and New Zealand.1,2 PE is the most common sexual 
dysfunction in men, with a global prevalence estimated to be between 20% and 40%.3–5 
The uncertainty about prevalence figures is due to the intimate nature of the condition 
and, until recently, the lack of a universal evidence-based definition. It is probable that 
many men do not admit to having the condition and do not seek medical advice.
PE is characterized by ejaculation prior to, or soon after, vaginal penetration with 
minimal stimulation, with the male having no control over ejaculation. Definitions have 
been published by the International Society for Sexual Medicine and in the Diagnostic 
Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), 
with the key point being the uncontrolled brevity of sexual intercourse.6–8 The negative 
consequences of PE are significant, and affect both the male and female partner. 
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As well as obvious sexual dissatisfaction, the condition can 
cause personal distress, low self-esteem, and interpersonal 
difficulty.5,9–11
Dapoxetine belongs to a class of drugs called selective 
serotonin reuptake inhibitors (SSRIs) which are frequently 
used to treat depression. Prior to the availability of 
dapoxetine, psychotherapy (eg, cognitive behavior therapy) 
was widely used to treat PE. More recently, several SSRIs 
(other than dapoxetine) have been used off-label to treat 
PE.12,13 These SSRIs were not developed to treat PE,12 in 
contrast with dapoxetine which was specifically developed 
for this purpose and has a different pharmacological profile 
to the other SSRIs,14–17 with properties making it suitable for 
on-demand dosing.1
The aims of this article are to review the current evidence 
for use of dapoxetine in the treatment of PE, including the 
ability of the drug to not only increase time to ejaculation 
post-penetration, termed intravaginal ejaculatory latency 
time (IELT), but also to improve patient self-esteem, 
  satisfaction with sexual intercourse, and perceived control 
over ejaculation.
Methods
Literature searches were carried out in August 2011 using 
PubMed (http://www.ncbi.nlm.nih.gov/pubmed), the 
Cochrane Database of Systematic Reviews (http://www. 
thecochranelibrary.com/view/0/AboutTheCochraneLibrary.
html#CDSR), NHS Evidence (http://www.evidence.nhs.uk/
search?q=dapoxetine&pa=2), and the National Institute for 
Health and Clinical Excellence (NICE, http://www.nice.
org.uk). These databases were searched using the terms 
“  dapoxetine” or “dapoxetine AND premature ejaculation”.
Articles involving dapoxetine for the treatment of PE were 
identified, with priority given to systematic reviews, meta-
analyses and integrated analyses, double-blind, randomized, 
placebo-controlled clinical trials (RCTs), and nonrandomized 
observational studies. Only articles   published in English were 
selected for inclusion. The references listed in identified 
articles were used as a further source of relevant studies.
Overview of premature ejaculation
PE is highly prevalent and, due to the nature of the disorder, 
is likely to be under-reported and undertreated.5,18 Reported 
prevalence has also been variable due to the previous lack of 
an evidence-based definition. In the past, physicians   generally 
considered PE to have a psychological element, hence 
the   historical use of psychotherapy to treat the   condition. 
However, in recent years, the biological component has 
become more widely understood, and pharmacotherapy is 
the new focus for the treatment of PE.
Two types of PE have been widely recognized, ie,   lifelong 
(primary) and acquired (secondary) PE. Lifelong PE is 
present from the first sexual experience onwards, occurs in 
almost all attempts at intercourse, and is considered to have 
a neurobiological etiology. Secondary PE occurs later in life 
after a period of perceived normal ejaculatory control, and 
may have a psychological and neurobiological   etiology. This 
type of PE may be triggered by stress or linked to adverse 
events associated with medications.19,20 Waldinger et al 
suggested that, in addition to these well known types of PE, 
there are two other subtypes, ie, natural variable PE and 
premature-like ejaculatory dysfunction.21 Natural variable 
PE refers to those men reporting occasional early ejacula-
tion in the course of normal events, whilst with the latter, 
men experience or complain of PE while having normal or 
prolonged IELT.22,23
Despite the above classifications, features common to all 
PE are an inability to control ejaculation, ejaculation prior 
to/soon after vaginal penetration, embarrassment, low self-
esteem, personal distress, and often interpersonal difficulty 
and relationship problems as a result of the lack of sexual 
satisfaction for both the man and his partner.6,7 The first 
evidence-based definition of lifelong PE has recently been 
published by the International Society for Sexual Medicine, 
and includes the criterion of “ejaculation which always or 
nearly always occurs prior to or within about 1 minute of 
vaginal penetration”, ie, an IELT of 1 minute or less. Other 
specified criteria are “… the inability to delay ejaculation on 
all or nearly all vaginal penetrations, and negative personal 
consequences, such as distress, bother, frustration and/or 
the avoidance of sexual intimacy”.8 Prior to this, researchers 
recruiting patients for clinical studies of PE tended to use the 
definition given in the DSM-IV-TR, which is similar to that 
of the International Society for Sexual Medicine, but does 
not specify an IELT threshold.6
The etiology of PE is multifactorial, and associations 
with psychological, environmental, endocrine, and neuro-
biological factors have been made. Control of ejaculation 
is under neuronal control from the supraspinal level and 
involves various neurotransmitters, the most widely studied 
of which is serotonin (5-hydroxytryptamine, 5-HT). The role 
of 5-HT in the pathophysiology of PE is complex, with at 
least three receptor subtypes (5-HT1a, 5-HT1b, 5-HT2c) being 
known to play a role.24 Recently, there has been   interest 
in investigating a potential genetic basis for PE.25 It is 
  postulated that a polymorphism of the serotonin   transporter 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2
McCarty and DinsmoreCore Evidence 2012:7
gene (5-HTT) may be associated with the response to 
  treatment with SSRIs.26
Current therapeutic options
Due to a perceived psychosomatic aspect of PE, psychother-
apy, such as sex therapy or cognitive therapy, has been widely 
used historically to treat PE.12 The aim of such treatment is 
to encourage self-confidence and improve communication 
and intimacy between PE patients and their partners, in the 
hope of improving performance and reducing the anxiety 
associated with intercourse. Behavioral methods are also 
used to reduce the urgency to ejaculate, including squeezing 
the glans of the penis or intermittent penetration, although 
the latter may actually lead to prolonged sexual frustration 
rather than greater penetrative time.27 Despite some reported 
short-term efficacy, there is little evidence of any long-term 
benefit associated with these treatment methods.1,9,28,29
The use of topical anesthetic creams was first described 
by Schapiro in 1943, the rationale being that reduced penile 
sensitivity would result in prolongation of sexual intercourse 
without adversely affecting the sensation of ejaculation.30,31 
Prilocaine/lidocaine cream (EMLA®) has commonly been 
used off-license in the first-line management of PE. A novel 
metered-dose aerosol spray of lidocaine/  prilocaine (TEMPE®) 
was found to increase IELT significantly   compared with 
placebo (up to an eight-fold increase in one study) but 
is   awaiting licensing.30,32–34 On face value, these topical 
  treatments may appear ideal for on-demand use in PE, but 
they have several disadvantages, including genital numbness 
for both the patient and partner, reduced ability to maintain 
an erection, and messy application.12 As a result, these topical 
therapies have never achieved widespread acceptability.
The phosphodiesterase type 5 inhibitors, which are 
licensed for the treatment of erectile dysfunction, have been 
evaluated for use in PE. Despite their success in treating 
erectile dysfunction, there are limited data to support their 
use in PE alone. The only randomized, placebo-controlled, 
double-blind multicenter study evaluating sildenafil showed 
a 2.6-fold increase in IELT, but this was not statistically 
significant from placebo.35 However, it did show an improve-
ment in ejaculatory control, confidence, and satisfaction 
in patient-derived questionnaires. A systematic review of 
14 clinical trials assessing the efficacy of phosphodiesterase 
type 5 inhibitors and on-demand SSRIs concluded that wide 
ranges of IELT changes were due to inconsistencies in study 
designs and therefore are difficult to interpret reliably.36
Several years ago, the observation that one of the 
adverse effects of SSRIs when used to treat depression and 
other psychological disorders, ie, anorgasmia or delayed 
ejaculation, suggested SSRIs as a possible pharmacotherapy 
for PE.8,9 Subsequent research on the central and presyn-
aptic involvement of 5-HT in ejaculation confirmed the 
mechanism of action of SSRIs in PE and marked a new era 
in   pharmacotherapy for the condition.24
A number of SSRIs are currently used off-label in 
long-term daily dosing regimens for treatment of PE, 
  including paroxetine, fluoxetine, fluvoxamine, sertraline, and 
  citalopram.2 Paroxetine appears to be particularly effective 
at improving IELT; in one study, paroxetine 20–40 mg per 
day over a 6-week period was found to increase median IELT 
by 9.5 minutes, while placebo provided no change in IELT 
(P = 0.002).37,38 Significantly increased IELT comes at a cost, 
because several adverse effects are   commonly   experienced 
with these SSRIs, including erectile   dysfunction, loss of 
libido, mood changes, and   discontinuation   syndrome.12 Dis-
continuation syndrome consists of a cluster of psychological 
and somatic symptoms, including dizziness, headache, agita-
tion, and insomnia, which may occur 1–3 days after stopping 
an SSRI and last for longer than 1 week, but subside on 
reintroduction of an SSRI.
A recent report by Koyunchu et al suggested that the 
use of escitalopram in the treatment of lifelong PE resulted 
in reduced semen parameters (specifically concentration, 
motility, and morphology) and could therefore have a 
  negative effect on male fertility.39 Further studies need to 
be done to establish a possible mechanism and determine if 
this observation is similar with other SSRIs.
Unlike the SSRIs mentioned above, dapoxetine was 
developed specifically for treatment of PE and is the only SSRI 
approved for treatment of the condition. What sets dapoxetine 
apart from other SSRIs currently used off-label to treat PE is 
its pharmacokinetic profile.15,16 Briefly, the   pharmacology of 
dapoxetine may be summarized as follows:
•	 Dapoxetine is rapidly absorbed following oral adminis-
tration, whereas other SSRIs take several days or even 
weeks to reach steady-state concentrations14
•	 Peak plasma levels of dapoxetine are reached in approxi-
mately 1 hour following a dose of 30 mg or 60 mg15,16
•	 Dapoxetine is rapidly eliminated; its initial half-life is 
approximately 1.4 hours for both doses, compared with 
21 hours to 4 days for other SSRIs14
•	 Dapoxetine has a terminal half-life of 18.7 hours for the 
30 mg dose and 21.9 hours for the 60 mg dose15
•	 Even with multiple dosing, the pharmacokinetics of 
dapoxetine are unchanged, and it does not appear to 
accumulate significantly.15
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These pharmacokinetic characteristics make dapoxetine 
ideal for on-demand dosing, which reduces the   probability of 
unwanted side effects.15,40 Previous Phase II studies   identified the 
optimal dose to be 30 mg initially, with an increase to 60 mg (the 
maximum recommended dose) if required.   Pharmacodynamic 
studies identified the optimal dose   administration time to be 
1–3 hours before sexual intercourse.41
Clinical evidence for dapoxetine
From the literature searches, nine publications were   identified 
for inclusion in the following evaluation of the clinical 
evidence for dapoxetine in the treatment of PE. These 
  comprised three integrated analyses, six randomized placebo-
controlled studies (two studies of identical design are only 
available as an integrated analysis), one subanalysis of two 
studies, and one long-term extension study.
In the following discussion, to aid critical analysis of the 
studies included for assessment, each publication has been 
assigned a “quality of evidence” rating based on the criteria 
shown in Table 1.
Increase in IELT
Due to the nature of PE, a change in IELT is the only disease-
orientated outcome that is regularly measured and reported. 
Other frequently reported outcomes are   necessarily patient-
reported outcomes, and these are discussed later. Table 2 
provides a summary of the identified studies reporting 
changes in IELT with dapoxetine and the quality of evidence 
supporting these changes. All of these studies were carried 
out before the recent definition of lifelong PE was published 
by the International Society for Sexual Medicine,8 so the 
recruitment criteria are based on the definition given by the 
DSM-IV-TR,6 with the added criterion of IELT #2 minutes 
in at least 75% of sexual events (at least 90% of sexual events 
in Safarinejad43). In the studies listed in Table 2, IELT was 
measured using a stopwatch held by the partner during epi-
sodes of sexual intercourse and averaged over the specified 
baseline and treatment periods.
Stopwatch-measured IELT was reported in seven 
publications listed in Table 2, with the duration of these 
studies ranging from 9 to 24 weeks. Mean average IELT 
was significantly increased in all cases following treat-
ment with dapoxetine 30 mg or 60 mg, with end-of-study 
values being significantly greater than those for placebo, 
indicating an improvement in PE. The RCT by McMahon 
et al demonstrated significant increases from baseline in mean 
(± standard deviation) IELT after just one dose of   dapoxetine, 
ie, 30 mg (1.1 [0.45]–2.7 [2.68] minutes), 60 mg (1.1 [0.48]–
3.0 [3.19] minutes), and placebo (1.0 [0.47]–1.8 [1.71]; 
P , 0.001) for both doses of dapoxetine vs placebo.44 This 
significant difference from placebo was evident at all time 
points to the end of the study.
Of the seven studies in Table 2, four reported arithmetic 
and geometric means of average IELT, while three reported 
only one or the other. Geometric means give more conser-
vative results that are less affected by data outliers, thus the 
values tend to be lower than those for arithmetic means. 
Where both geometric and arithmetic means were presented, 
the results for average IELT were similar for both methods. 
For example, in the integrated analysis of five Phase III 
studies, geometric mean IELT increased from 0.8 minutes at 
baseline in all groups to 2.0 and 2.3 minutes in those taking 
dapoxetine 30 mg and 60 mg, respectively, compared with 
1.3 minutes for those taking placebo (both P , 0.001).45 The 
corresponding arithmetic means increased from 0.9 minutes 
at baseline to 3.1, 3.6, and 1.9 minutes, respectively (both 
P , 0.001 vs placebo, Table 2).
Even in more extreme cases of PE, in which baseline 
IELT was very short, treatment with dapoxetine effec-
tively increased IELT. In the integrated analysis of two 
Phase III studies by Pryor et al,46 increases from baseline 
in   average IELT at 12 weeks were significantly greater 
for either dose of dapoxetine (30 mg or 60 mg) than for 
placebo in the   subgroups of patients with baseline average 
IELTs #1 minute and #30 seconds. The subanalysis of 
Table 1 Levels of evidence applied to studies included in this 
review
Strength of  
evidence
Criteria Number 
of studies
Level 1 Strong evidence from at least  
one systematic review, meta-analysis,  
or integrated analysis
3
Level 2 Evidence from randomized  
controlled trials
7*
Level 3 Evidence from nonrandomized well  
designed trials, single-group pre/post  
intervention, cohort, time series,  
or matched-case control studies
1
Level 4 Evidence from well designed, 
nonexperimental, observational  
studies from more than one center  
or research group
0
Level 5 Opinions of respected authorities,  
based on clinical experience,  
descriptive studies, and reports  
of expert committees
0
Note: *Two trials of identical design are only available as an integrated analysis16 and 
are included in the level 1 category. 
Adapted from Clark and Mucklow.42
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4
McCarty and DinsmoreCore Evidence 2012:7
these studies by Shabsigh et al49 highlighted the importance 
of perceived control over ejaculation for achieving increases 
in IELT. Patients who reported at least a two-category 
improvement in control after 12 weeks of dapoxetine therapy 
recorded a mean change in IELT of 3.8 (0.9–4.7) minutes, 
whereas those who reported less than a two-category 
improvement in control recorded a mean change in IELT 
of 0.8 (0.9–1.7) minutes (Table 2). Overall, the consistent 
nature of the results from the studies identified indicates 
substantial evidence for a significant increase in IELT with 
dapoxetine 30 mg and 60 mg, compared with placebo, in 
adult patients with PE.
Patient-reported outcomes
In studies of PE, patient-reported outcomes form an   important 
part of the evidence base because of the many ways in 
which PE can affect psychological wellbeing and quality of 
life, both for the patient and their sexual partner. The most 
Table 2 Summary of evidence for end-of-study changes in intravaginal ejaculation latency time following treatment of premature 
ejaculation with dapoxetine
Level of  
evidence
Design Treatment  
and dose
Intravaginal ejaculatory latency time  
(minutes)
P value  
(vs placebo)
Reference
Baseline Geometric  
mean (SE)
Arithmetic 
mean (SD)
1 Integrated analysis  
of five studies
DPX 30 mg or  
60 mg, or PBO
DPX 30 
DPX 60 
PBO 
DPX 30 
DPX 60 
PBO
0.8 (1.02) 
0.8 (1.02) 
0.8 (1.02) 
0.9 (0.49) 
0.9 (0.49) 
0.9 (0.48)
2.0 (1.03) 
2.3 (1.03) 
1.3 (1.02)
 
 
 
3.1 (3.91) 
3.6 (3.85) 
1.9 (2.43)
,0.001 
,0.001 
– 
,0.001 
,0.001 
–
McMahon  
et al45
1 Integrated analysis  
of two studies
DPX 30 mg or  
60 mg, or PBO
DPX 30 
DPX 60 
PBO
0.92 (0.50) 
0.91 (0.48) 
0.90 (0.47)
2.78 (3.48) 
3.32 (3.68)† 
1.75 (2.21)
,0.0001 
,0.0001 
–
Pryor et al46
1 Integrated  
analysis of  
two studies#
DPX 30 mg or  
60 mg, or PBO
Acquired PE 
 
Geometric 
Arithmetic 
Lifelong PE 
Geometric 
Arithmetic
 
 
0.9 (1.03) 
1.08 (0.48) 
 
0.8 (1.02) 
0.92 (0.48)
 
 
 
2.5; 2.9; 1.7 
 
2.2; 2.4; 1.2
 
 
 
4.0; 4.1; 2.5 
 
3.3; 3.6; 1.9
 
 
,0.001 
,0.001 
 
,0.001 
,0.001
Porst et al47
2 Double-blind  
RCT, 12 week 
n = 1067
DPX 30 mg or  
60 mg, or PBO
DPX 30 
DPX 60 
PBO 
DPX 30 
DPX 60 
PBO
1.0 (1.03) 
0.9 (1.04) 
0.90 (1.04) 
1.1 (0.45) 
1.1 (0.48) 
1.0 (0.47)
2.7 (1.05) 
3.1 (1.05) 
1.8 (1.05)
 
 
3.9 (3.94) 
4.2 (3.97) 
2.4 (2.05)
,0.0001 
,0.0001 
– 
,0.001 
,0.001 
–
McMahon  
et al44
2 Double-blind  
RCT, 24 weeks, 
n = 1162
DPX 30 mg or  
60 mg, or PBO
DPX 30 
DPX 60 
PBO 
DPX 30 
DPX 60 
PBO
0.7 (1.04) 
0.7 (1.04) 
0.7 (1.04) 
0.9 (0.50) 
0.9 (0.50) 
0.9 (0.50)
1.8 (1.06) 
2.3 (1.06) 
1.1 (1.06)
 
 
3.1 (4.88) 
3.5 (3.80) 
1.9 (2.89)
,0.001 
,0.001 
– 
,0.001 
,0.001 
–
Buvat et al48
2 Double-blind  
RCT, 12 weeks, 
n = 212
DPX 60 mg  
(30 mg twice- 
daily), or PBO
DPX 60 
PBO
0.47 
0.52
3.22 
0.9
0.001a 
0.08a
Safarinejad43
2 Subanalysis of 
integrated  
analysis by  
Pryor et al46
DPX 30 mg or  
60 mg, or PBO 
(Authors 
combined the  
data for DPX  
30 and 60 mg)
DPX 
Patients with at  
least a 2-category  
increase in control 
Patients with less 
than a 2-category 
increase in control
 
0.9 (0.47) 
 
 
0.9 (0.47)
 
4.7 (4.41) 
 
 
1.7 (1.90)
 
Not reported 
 
 
Not reported
Shabsigh  
et al49
Notes: #Only data for patients without erectile dysfunction are shown for consistency with other studies; †P , 0.0001 vs 30 mg dapoxetine; aP value is based on fold-increase 
from baseline, not difference from placebo as stated for the other studies. 
Abbreviations: RCT, randomized controlled trial; SE, standard error; SD, standard deviation; PBO, placebo; DPX, dapoxetine; PE, premature ejaculation.
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  frequently applied instrument in studies of PE is the Premature 
  Ejaculation Profile, which is a validated tool designed to inves-
tigate various domains in PE and assess treatment efficacy. It 
comprises four self-reported items, each scored on a five-point 
scale, ie, perceived control over ejaculation, satisfaction with 
sexual intercourse, personal distress related to ejaculation, and 
interpersonal difficulty related to ejaculation.50
In addition, the Clinical Global Impression (CGI) of change 
is a validated instrument often used to give a measurement of 
overall perceived change in PE following treatment. The CGI 
(also called the patient-reported global impression of change 
in some studies) comprises just one item, ie, “  Compared to 
the start of the study, how would you describe your premature 
ejaculation now?” Patients rate their response on a seven-point 
scale (−3 to +3) as: much worse, worse, slightly worse, no 
change, slightly better, better, or much better.51
Studies reporting patient responses to items on the 
  Premature Ejaculation Profile and the CGI of change are 
listed in Table 2, with quality of evidence indications. Each 
of the patient-reported outcomes is assessed individually 
below.
Perceived improvement in control  
over ejaculation
Changes from baseline in perceived control over ejaculation 
are reported for eight studies (Table 3). All three integrated 
analyses found significant improvements in control over 
ejaculation at study endpoint. In McMahon et al, in which 
the results from five RCTs were integrated, the propor-
tion of patients who reported at least “good” control after 
12 weeks of dapoxetine therapy increased from a baseline 
of 0.6% to 26.2% with dapoxetine 30 mg, and from 0.5% 
to 30.2% with dapoxetine 60 mg, compared with 0.3% to 
11.2% with placebo (P , 0.001 for both dapoxetine doses vs 
placebo).45
The integrated analysis by Porst et al of two studies showed 
no differences in control over ejaculation between those 
with lifelong or acquired PE (and no erectile dysfunction), 
  suggesting that the etiology of the two forms may be similar, 
given that dapoxetine treatment was equally effective.47 The 
proportions of patients reporting at least “good” control at 
baseline and end-of-study were as follows:
•	 Acquired PE, 1% at baseline to 32% at end-of-study 
(dapoxetine 30 mg); 1% to 35% (dapoxetine 60 mg), and 
1% to 19% (placebo)
•	 Lifelong PE, 0.5% at baseline to 29% at end-of-study 
(dapoxetine 30 mg); 0.5% to 28% (dapoxetine 60 mg), 
and 0.5% to 12% (placebo)47
Significant improvement in ejaculatory control with 
dapoxetine 30 mg or 60 mg, as compared with placebo, was 
found in all RCTs in Table 3. These improvements were 
noted not only at the end-of-study but at all time points in 
between.44,47,52
The long-term use of on-demand dapoxetine has been 
addressed in just one study (see Table 3), ie, a 9-month 
extension study of the two 12-week trials described by 
Pryor et al.47 All of the 1774 men enrolled in the extension 
study received on-demand dapoxetine 60 mg, regardless 
of prior treatment group in the original studies (dapoxetine 
30 mg, 60 mg, or placebo). At 9 months, approximately 70% 
of patients reported “fair”, “good”, or “very good” control 
over ejaculation.53 These data represent clear evidence of a 
significant improvement over placebo in perceived control 
over ejaculation in adult patients with PE taking dapoxetine 
30 mg or 60 mg on-demand.
Satisfaction with sexual intercourse
Changes from baseline in satisfaction with sexual intercourse 
were reported in eight studies (Table 3). All three integrated 
analyses found significant improvements in satisfaction with 
sexual intercourse at study endpoint. In the analysis of two 
12-week studies by Pryor et al, the proportion of patients 
receiving dapoxetine who reported at least “fair” satisfaction 
increased from approximately 50% at baseline to approxi-
mately 75% (dapoxetine 30 mg) and 80% (dapoxetine 60 mg) 
at end-of-study, compared with approximately 55% with 
placebo (P , 0.001 for both dapoxetine doses vs placebo; 
data estimated from Pryor et al).47 Furthermore, significant dif-
ferences from baseline were seen at every time point for both 
doses of dapoxetine vs placebo (weeks 4, 8, and 12). Impor-
tantly, the partners of subjects in these trials also reported sig-
nificant improvements in satisfaction with sexual intercourse 
at every time point, suggesting possible associated reductions 
in interpersonal difficulty (not measured in these studies). This 
integrated analysis also found a dose-dependent effect of 
dapoxetine, with significantly more patients on   dapoxetine 
60 mg reporting at least “fair” satisfaction at every time point 
compared with those on dapoxetine 30 mg.47   Subanalysis 
of the trials published by Shabsigh et al highlighted the 
impact of greater perceived control over ejaculation on 
other aspects of sexual experience, with 74% of patients 
having at least a two-category increase in control-rated 
satisfaction with intercourse of “good” or “very good” at 
end-of-study.49
The integrated analysis of two studies by Porst et al 
showed no differences in satisfaction with intercourse 
submit your manuscript | www.dovepress.com
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between those with lifelong or acquired PE (no erectile 
dysfunction), indicating that the two forms potentially 
share some pathophysiological elements.47 The proportions of 
patients reporting at least “good” satisfaction with intercourse 
at baseline and end-of-study (pooled 12-week data from a 
12-week and a 24-week study) were as follows:
•	 Acquired PE, 7% at baseline to 38% at end-of-study 
(dapoxetine 30 mg); 7% to 42% (dapoxetine 60 mg) and 
7% to 29% (placebo)
•	 Life-long PE, 10% at baseline to 40% at end-of-study 
(dapoxetine 30 mg); 10% to 38% (dapoxetine 60 mg) 
and 10% to 23% (placebo)
All three of the RCTs in Table 3 found significant 
improvements from baseline in satisfaction with intercourse 
compared with placebo at end-of-study and at all time points 
in between. For example, at end of the McMahon et al 
study, the proportions of patients who reported “good” or 
“very good” satisfaction with intercourse were 41.3% for 
dapoxetine 30 mg, 40.9% for dapoxetine 60 mg, and 29.0% 
for placebo (P , 0.001 for both doses of dapoxetine vs 
placebo).44
The effect of long-term dapoxetine treatment on satis-
faction with sexual intercourse was examined in the non-
randomized extension study by Steidle et al (see Table 3).54 
Irrespective of prior treatment (dapoxetine 30 mg, 60 mg, 
or placebo), long-term on-demand use of dapoxetine 60 mg 
resulted in more than 80% of patients reporting at least “fair” 
satisfaction with intercourse after 9 months.54 There is clear 
evidence from these studies that dapoxetine therapy in adult 
males with PE improves satisfaction with sexual intercourse 
in comparison with placebo.
Personal distress related to ejaculation
Five studies in Table 2 report changes from baseline in 
personal distress related to ejaculation, ie, two integrated 
analyses and three RCTs. Both integrated analyses found 
significant reductions in distress related to ejaculation at 
study endpoint following dapoxetine treatment. In the 
integrated analysis by McMahon et al, the proportions of 
patients who reported “quite a bit” or “extreme” personal 
distress decreased from 71.3% at baseline to 28.2% for 
dapoxetine 30 mg, and from 69.7% to 22.2% for dapox-
etine 60 mg, compared with 73.5% to 41.9% with placebo 
(P , 0.001 for both dapoxetine doses vs placebo).45 As 
with the measures of ejaculatory control and sexual sat-
isfaction, the integrated analysis of two studies by Porst 
et al found no differences in distress related to ejaculation 
between those with lifelong or acquired PE (and no erectile 
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dysfunction).47 The proportion of patients reporting “quite 
a bit” or “extreme” personal distress at baseline and end-
of-study were as follows:
•	 Acquired PE, 73% at baseline to 23% at end-of-study 
(dapoxetine 30 mg), 73% to 20% (dapoxetine 60 mg), 
and 73% to 41% (placebo)
•	 Life-long PE, 71% at baseline to 28% at end-of study 
(dapoxetine 30 mg), 71% to 22% (dapoxetine 60 mg), 
and 71% to 44% (placebo).
All three of the RCTs in Table 2 reporting changes in 
personal distress related to ejaculation found significant 
improvements with dapoxetine therapy from baseline 
compared with placebo at end-of-study. Furthermore, one 
of these studies also found significant differences between 
dapoxetine (both 30 mg and 60 mg) and placebo at all time 
points between baseline and end-of-study.44 In the RCT 
by Kaufman et al, the proportion of patients who reported 
being “not at all” or “a little bit” distressed by their ejacula-
tion   timing increased from approximately 5% at baseline to 
54.3% at end-of-study for those who received dapoxetine 
60 mg, compared with 35.3% for those who received 
  placebo.52 Thus, there is clear evidence that personal distress 
related to the timing of ejaculation is significantly reduced 
with dapoxetine treatment, compared with placebo, in adults 
with PE.
Interpersonal difficulty related  
to ejaculation
Changes from baseline in interpersonal difficulty related to 
ejaculation following dapoxetine therapy were reported in 
five studies (Table 3). Two integrated analyses reporting 
this outcome found significant reductions in interpersonal 
difficulty related to ejaculation compared with placebo at 
study endpoint, ie, McMahon et al (integrated results from 
five studies) and Porst et al (integrated results from two 
studies).44,47 In the McMahon analysis, the proportions of 
patients who reported “quite a bit” or “extreme” interper-
sonal difficulty decreased from 36.1% at baseline to 12.3% 
for dapoxetine 60 mg (there is an error in the publication 
for the dapoxetine 30 mg results), compared with 38.5% to 
23.8% with placebo (P , 0.001 for dapoxetine 60 mg vs 
placebo).44
The integrated analysis by Porst et al showed no dif-
ferences in interpersonal difficulty related to ejaculation 
between those with lifelong or acquired PE (and no erectile 
dysfunction), adding further weight to the argument that 
lifelong and acquired PE have some shared etiology.47 The 
proportions of patients reporting “quite a bit” or “extreme” 
interpersonal difficulty at baseline and end-of-study were 
as follows:
•	 Acquired PE, 40% at baseline to 11% at the 12-week 
end-of-study (dapoxetine 30 mg and 60 mg) and 40% to 
24% (placebo)
•	 Lifelong PE, 34% at baseline to 14% at end-of-study 
(dapoxetine 30 mg), 34% to 11% (dapoxetine 60 mg), 
and 34% to 26% (placebo)
All three of the RCTs in Table 2 reporting this outcome 
found significant improvements from baseline in interper-
sonal difficulty related to ejaculation compared with placebo 
at the study endpoint following dapoxetine treatment. In the 
RCT by Kaufman et al, the proportion of patients taking 
on-demand dapoxetine 60 mg who reported “not at all” or 
“a little bit” of interpersonal difficulty related to ejaculation 
increased from 40.9% at baseline to 76.8% at the 9-week 
study endpoint, compared with 43.0% to 64.2% for those tak-
ing placebo.52 Although comparative statistical analyses have 
not been employed in all of the above studies, the evidence 
suggests that dapoxetine (30 mg or 60 mg) is associated with 
an improvement in ejaculation-related interpersonal difficulty 
when compared with placebo.
CGI of change in premature ejaculation
The CGI of change in PE is a measure of a patient’s overall 
perception of how their PE has changed following treatment. 
Patients’ CGI responses following dapoxetine therapy are 
reported in six studies listed in Table 3 (note that three of 
these studies refer to this as patient global impression of 
change in PE or patient-reported global impression). The two 
integrated analyses reporting this outcome found significantly 
better CGI scores compared with placebo at study endpoint. 
In one of these, the proportions of patients who reported their 
condition to be “slightly better”, “better”, or “much better” 
at the end of the study (12 weeks) were 58% (dapoxetine 
30 mg) and 67% (dapoxetine 60 mg), compared with 26% 
with placebo (P , 0.0001 for both dapoxetine doses vs 
placebo).47 Similarly, the study by McMahon et al found 
the proportions of patients who reported their PE to be at 
least “slightly better” at 12 weeks were 62.1% (dapox-
etine 30 mg) and 71.7% (dapoxetine 60 mg), compared 
with 36.0% with placebo (P , 0.0001 for both dapoxetine 
doses vs placebo).45
All three of the RCTs in Table 3 found significantly better 
CGI scores with dapoxetine therapy compared with placebo 
at the study endpoints. At the 12-week end-of-treatment 
phase in the McMahon study, the proportions of patients 
who reported their PE to be at least “slightly better” were 
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and placebo).52 This trial was only 9 weeks in duration, 
but positive results for this outcome measure were evident 
in the   longer term. After 24 weeks of dapoxetine therapy, 
the trial by Buvat et al found 25.3% and 37.1% of patients 
achieved the composite patient-reported outcome with 
dapoxetine 30 mg and 60 mg, respectively, compared with 
13.0% with placebo (P , 0.001 for both dapoxetine doses vs 
placebo).48
Economic evidence
Our literature search found no published health economics 
studies on the use of dapoxetine in adult patients with PE. 
The economic costs of dapoxetine should be assessed indi-
vidually in all the countries where it is approved, since the 
relative costs to the health care provider differ according to 
local health care structure, currency, and costs of alterna-
tive therapy. Country-specific health economics studies are 
needed to answer the following questions:
•	 Is on-demand use of dapoxetine more cost-effective than 
long-term once-daily use of other SSRIs for treatment 
of PE?
•	 Is on-demand use of dapoxetine more cost-effective than 
psychotherapy?
Dosage, administration,  
and formulation
Oral dapoxetine is indicated for the treatment of men aged 
18–64 years with premature ejaculation. The recommended 
starting dose is 30 mg (administered with water) as needed, 
1–3 hours prior to sexual intercourse (with a maximum 
dosing frequency of once every 24 hours). The dose may be 
increased to 60 mg (the maximum recommended dose) based 
on efficacy and tolerability. Each film-coated tablet contains 
either 30 mg or 60 mg dapoxetine hydrochloride, and may 
be administered with or without food.
Dapoxetine is contraindicated in men with moderate to 
severe hepatic impairment and in those receiving concomi-
tant therapy with potent cytochrome P450 3A4 inhibitors 
(eg, ketoconazole, ritonavir, telithromycin), thioridazine, 
monoamine oxidase inhibitors, serotonin reuptake inhibitors 
(eg, SSRIs, serotonin-norepinephrine reuptake inhibitors, 
tricyclic antidepressants) or other medicinal/herbal prod-
ucts with serotonergic effects (eg, hypericum [St John’s 
wort]). Dapoxetine is not recommended in men with severe 
renal impairment, and caution is advised in men with mild 
to moderate renal impairment. Alcohol and recreational 
drugs should be avoided when taking dapoxetine. The 
above information is taken from the product monograph 
71.4% (dapoxetine 30 mg), 79.2% (dapoxetine 60 mg), and 
52.8% (placebo, P , 0.001 for both doses of dapoxetine vs 
placebo).44 The corresponding proportions for patients in 
this study who reported their PE to be at least “better” were 
37.4% (dapoxetine 30 mg), 41.5% (dapoxetine 60 mg), and 
22.0% (placebo, P , 0.001 for both doses of dapoxetine vs 
placebo).44
The subanalysis by Shabsigh et al (of the integrated 
analysis reported by Pryor et al47) showed how perceived 
control over ejaculation is important for achieving an 
improved overall impression of PE.49 For example, 38.7% 
of patients who reported at least a one-category increase 
in control also reported a CGI rating of “better” or “much 
better”. Moreover, 67.1% of patients who reported at least a 
two-category increase in control also reported a CGI rating 
of “better” or “much better”. Overall, dapoxetine (30 mg or 
60 mg) is clearly associated with greater perceived overall 
improvement in PE compared with placebo.
Patient-reported outcome-defined level 
of clinical benefit
Three of the RCTs in Table 3 also reported a predefined 
composite clinical outcome as a measure of clinical benefit 
following dapoxetine treatment.44,48,52 It has been previously 
established that this composite is associated with improve-
ments in IELT, satisfaction with intercourse, and the patients’ 
global perception of PE.49 The composite patient-reported 
outcome was defined as a “two-category or greater increase 
in perceived control over ejaculation, and a one-category or 
greater decrease in ejaculation-related personal distress”.
All three studies found a significantly greater proportion 
of patients achieving the composite patient-reported outcome 
with dapoxetine 30 mg or 60 mg than with placebo at the 
end of the treatment period. In the paper by McMahon et al, 
the proportions achieving the composite patient-reported 
outcome were 34.7% (dapoxetine 30 mg) and 37.2% (dapox-
etine 60 mg), compared with 21.7% for placebo (P , 0.001 
for both doses of dapoxetine vs placebo). In the same study, 
patients achieving the composite patient-reported outcome 
reported longer IELTs than those reported by the overall 
treatment groups, ie, 5.4 minutes vs 3.9 minutes (dapoxetine 
30 mg) and 4.2 minutes (dapoxetine 60 mg).44
The proportion of patients who achieved the composite 
patient-reported outcome was even larger in the Kaufman 
et al study in which 47.6% of patients who took dapox-
etine 60 mg on-demand achieved the composite patient-
reported outcome, compared with 21.7% of those taking 
placebo (P , 0.001 for the difference between dapoxetine 
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(http://www.sustinexprematureejaculation.com/pdf/  Sustinex.
pdf). Studies with concomitant use of dapoxetine and phos-
phodiesterase type 5 inhibitors do not show any significant 
interaction with tadalafil 20 mg or sildenafil 100 mg.53
Place in therapy
The strongest evidence for the use of dapoxetine in adult 
males with premature ejaculation is for the main disease-
oriented outcome of IELT, reported in seven of the nine 
publications identified in our literature search (see Table 4). 
Dapoxetine significantly and consistently increased IELT by 
approximately 3–4 minutes, representing a 3–4-fold increase 
in IELT. Placebo, in contrast, generally resulted in just a 
two-fold increase in IELT. The disease-oriented efficacy of 
dapoxetine has been shown in the studies examined here to 
be supported by positive effects in all patient-reported out-
comes, which together indicate a significant improvement 
in wellbeing and quality of life. Importantly, clear evidence 
was found for improvements in interpersonal relationships, 
suggesting that both sexual partners benefitted from dapox-
etine treatment.
Despite a historical distinction between lifelong and 
acquired PE based on the time of life at which PE occurs, 
there is no evidence for a difference in response to dapoxetine 
in males with lifelong or acquired PE. Although increases in 
IELT were generally slightly smaller for those with lifelong 
PE than those with acquired PE (see Table 2), the differences 
were not deemed sufficiently large to discriminate between 
them. Moreover, differences between the two PE subtypes 
were less evident for patient-reported outcomes. This adds 
weight to the proposal for a single, unified definition of PE. 
However, this evidence is based on just one integrated 
analysis of two trials so further research is needed to verify 
these data.47
It is encouraging that the results obtained with dapox-
etine therapy during trials of 9–24 weeks’ duration have 
been shown to be maintained during long-term on-demand 
use.54 However, it must be noted that evidence for this pres-
ently comes from one 9-month study of level 3 quality (it 
was nonrandomized and had no control group) in which 
patient-reported outcomes were measured, but not IELT. 
Therefore, more trials are required to add further evidence 
for the efficacy of long-term dapoxetine use in PE.
The great benefit of dapoxetine for the treatment of PE 
when compared with other SSRIs is that it can be taken as 
needed, which not only allows great flexibility and conve-
nience but also limits exposure to adverse events. In all the 
studies examined above, dapoxetine tolerability has been 
consistently favorable; adverse events associated with dapox-
etine are dose-dependent and tend to be nonsevere and non-
serious. The most commonly reported treatment-emergent 
adverse events were nausea, dizziness, somnolence, diarrhea, 
headache, and vomiting. Table 5 shows the frequency of these 
treatment-emergent adverse events in the RCTs examined 
Table 4 Summary of core evidence for dapoxetine in the treatment of lifelong or acquired premature ejaculation
Outcome measure Evidence Implications
Disease-oriented evidence
Increase in intravaginal ejaculatory latency time Substantial Dapoxetine is consistently better than placebo at significantly 
increasing intravaginal ejaculatory latency time
Patient-oriented evidence
Perceived improvement in control over ejaculation Clear Dapoxetine is better than placebo at giving men greater 
perceived control over ejaculation
Greater satisfaction with sexual intercourse Clear Dapoxetine gives patients greater satisfaction with intercourse 
compared with placebo
Less personal distress related to ejaculation Clear Distress ratings are significantly reduced with dapoxetine 
compared with placebo
Less interpersonal difficulty related to ejaculation Clear Significantly reduced ratings for interpersonal difficulty with 
dapoxetine compared with placebo
Improved clinical global impression of change in  
premature ejaculation
Clear More patients who received dapoxetine reported a positive 
change in premature ejaculation compared with those who 
received placebo
Economic evidence
On-demand use of dapoxetine is more  
cost-effective than long-term once-daily use of  
other selective serotonin reuptake inhibitors for  
treatment of premature ejaculation
No evidence Health economics studies are needed
On-demand use of dapoxetine is more cost-effective  
than psychotherapy
No evidence Health economics studies are needed
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above for efficacy (please refer to the original publications 
for full lists of adverse events).
Less frequently reported treatment-emergent adverse 
events include erectile dysfunction, flushing, palpitations, 
upper respiratory tract infection, nasopharyngitis, loss of 
libido, insomnia, fatigue, dry mouth, anxiety, hyperhidrosis, 
abdominal pain, back pain, and asthenia.43,44,46,48
As may be expected, discontinuations due to treatment-
emergent adverse events in the studies described here were 
reportedly more frequent with dapoxetine than with   placebo, 
and more frequent with dapoxetine 60 mg than with 30 mg. For 
example, in the trial by McMahon et al, 1.7% of patients on 
dapoxetine 30 mg and 5.1% on dapoxetine 60 mg   discontinued 
the study, compared with 0.3% of patients on placebo.44 
Nausea and dizziness were the most common treatment-
emergent adverse events reported to cause   discontinuation.44 
Similarly, Buvat et al state nausea to be the most common 
treatment-emergent adverse event leading to discontinuation 
(1% of patients on dapoxetine 30 mg, 2.6% on dapoxetine 
60 mg, and 0.3% on placebo).48 In the trials by Pryor et al and 
Safarinejad, 5% and 6% of patients, respectively, discontinued 
due to treatment-  emergent adverse events.43,46
Data on cardiovascular adverse events associated with 
dapoxetine in PE are somewhat inconsistent. In the study 
reported by Buvat et al, one patient experienced ventricular 
tachycardia and another patient had a transient ischemic 
attack (both receiving dapoxetine 30 mg), and a third patient 
experienced syncope followed by sinus bradycardia and sinus 
arrest (after receiving dapoxetine 60 mg). A fourth patient 
experienced syncope while on the higher dapoxetine dose.48 
The trial by Kaufman et al reported syncope in two patients 
taking dapoxetine 60 mg on-demand and in two patients 
taking the same dose once daily.52 In contrast, only one 
patient on dapoxetine (30 mg, plus two on placebo) experi-
enced nonsustained ventricular tachycardia, and no patients 
reported any episodes of syncope in the McMahon et al 
trial, leading the authors to conclude that dapoxetine had no 
arrhythmogenic effects.44 A recent review of the cardiovas-
cular safety profile of dapoxetine has examined data from 
the complete dapoxetine development program, including 
preclinical and Phase I studies, as well as the Phase III RCTs 
included in this review. It was concluded that dapoxetine is 
associated with vasovagal-mediated syncope (a temporary 
inability of the brain to control blood pressure and heart rate 
adequately causing syncope), but otherwise caused no other 
cardiovascular adverse events.55
Conclusion
Dapoxetine is the only drug specifically formulated and 
licensed for PE in adult males. The unique pharmacology of 
dapoxetine makes it ideal for on-demand dosing, allowing 
great convenience and flexibility for the patient. The clinical 
evidence published to date indicates that dapoxetine 30 mg 
or 60 mg is an efficacious and tolerable treatment for lifelong 
and acquired PE, leading to significant improvement not 
only in the main disease symptom of IELT, but also in all 
patient-reported outcomes. Dapoxetine is clearly a   promising 
  treatment option for PE, and its use can result in greater quality 
Table 5 Summary of frequently reported treatment-emergent adverse events in trials of dapoxetine for the treatment of premature 
ejaculation
Reference Design Treatment  
and dose
Treatment-emergent adverse events (% patients)
Nausea Diarrhea Headache Dizziness Somnolence Vomiting
Pryor et al46,^ Integrated  
analysis of  
two studies
DPX 30 mg or  
60 mg, or PBO
DPX 30 
DPX 60 
PBO
8.7 
20.1 
1.9
3.9 
6.8 
1.4
5.9 
6.8 
4.0
3.0 
6.2 
0.8
3.2 
3.7 
0.2
–
McMahon et al44,* Double-blind  
RCT, 12 weeks,  
n = 1067
DPX 30 mg or  
60 mg, or PBO
DPX 30 
DPX 60 
PBO
10.5 
26.4 
2.0
2.0 
1.7 
0.8
3.4 
4.8 
2.0
10.5 
18.8 
3.9
3.4 
6.2 
0.6
0.3 
2.5 
0
Buvat et al48 Double-blind  
RCT, 24 weeks 
n = 1162
DPX 30 mg or  
60 mg, or PBO
DPX 30 
DPX 60 
PBO
16.5 
30.6 
2.9
3.9 
11.3 
1.6
6.4 
13.6 
8.3
7.7 
13.4 
2.6
3.9 
7.2 
1.0
1.3 
3.1 
0.5
Kaufman et al52,∼ Double-blind  
RCT, 9 weeks,  
n = 1238
DPX 60 mg or  
PBO
DPX 60 
PBO
15.3 
1.6
6.1 
2.0
8.1 
6.1
10.2 
2.9
3.7 
0.8
–
Safarinejad43 Double-blind  
RCT, 12 weeks,  
n = 212
DPX 60 mg  
(30 mg twice  
daily), or PBO
DPX 60 
PBO
5.4 
1.0
5.4 
0
4.3 
1.0
3.2 
0
– –
Notes: ^Treatment-emergent adverse events more frequent with dapoxetine than with placebo; *occurring in $1% of subjects; ∼occurring in $2% of subjects. 
Abbreviations: RCT, randomized, placebo-controlled trial; PBO, placebo; DPX, dapoxetine.
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of life for the patient and their sexual partner. With the recent 
greater emphasis on research in the field of PE, it is hoped that 
the evidence base for a range of   treatments, both topical and 
oral, will grow and prove   valuable for patients.56
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